Allogeneic bone marrow transplantation in 24 patients with multiple myeloma reported to the EBMT registry

G. Gahrton, S. Tura, M. Flesch, A. Gratwohl, P. Gravett, A. Lindeberg, G. Lucarelli, M. Michallet, J. Reiffers, O. Ringden, J. Nikoskelainen, M. T. Van Lint, J. P. Vernant, F. E. Zwaan

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Twenty-four patients with multiple myeloma received an allogeneic bone-marrow graft from HLA-compatible sibling donors (n = 23), or a twin donor (n = 1). Eighteen patients are alive, 1-36 months post bone marrow transplantation (median 14 months). Ten of these patients had no signs of multiple myeloma as judged by immunoglobulins in serum, light chains in urine, or the percentage of plasma-cells in bone-marrow aspirate. Bone lesions on X-ray were mainly unchanged. Six patients died from transplant-related complications 3 weeks to 5 months post transplantation. One of these patients had severe acute graft-versus-host disease (aGVHD). In other patients aGVHD was a minor problem. Allogeneic bone-marrow transplantation appears to be a promising method for treatment of a selected group of patients with multiple myeloma.

Original languageEnglish
Pages (from-to)181-186
Number of pages6
JournalHematological Oncology
Volume6
Issue number2
DOIs
Publication statusPublished - 1988

Fingerprint

Homologous Transplantation
Multiple Myeloma
Bone Marrow Transplantation
Registries
Graft vs Host Disease
Bone Marrow
Tissue Donors
Transplants
Plasma Cells
Immunoglobulins
Siblings
Transplantation
X-Rays
Urine
Light
Bone and Bones
Serum

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Gahrton, G., Tura, S., Flesch, M., Gratwohl, A., Gravett, P., Lindeberg, A., ... Zwaan, F. E. (1988). Allogeneic bone marrow transplantation in 24 patients with multiple myeloma reported to the EBMT registry. Hematological Oncology, 6(2), 181-186. https://doi.org/10.1002/hon.2900060219

Allogeneic bone marrow transplantation in 24 patients with multiple myeloma reported to the EBMT registry. / Gahrton, G.; Tura, S.; Flesch, M.; Gratwohl, A.; Gravett, P.; Lindeberg, A.; Lucarelli, G.; Michallet, M.; Reiffers, J.; Ringden, O.; Nikoskelainen, J.; Van Lint, M. T.; Vernant, J. P.; Zwaan, F. E.

In: Hematological Oncology, Vol. 6, No. 2, 1988, p. 181-186.

Research output: Contribution to journalArticle

Gahrton, G, Tura, S, Flesch, M, Gratwohl, A, Gravett, P, Lindeberg, A, Lucarelli, G, Michallet, M, Reiffers, J, Ringden, O, Nikoskelainen, J, Van Lint, MT, Vernant, JP & Zwaan, FE 1988, 'Allogeneic bone marrow transplantation in 24 patients with multiple myeloma reported to the EBMT registry', Hematological Oncology, vol. 6, no. 2, pp. 181-186. https://doi.org/10.1002/hon.2900060219
Gahrton, G. ; Tura, S. ; Flesch, M. ; Gratwohl, A. ; Gravett, P. ; Lindeberg, A. ; Lucarelli, G. ; Michallet, M. ; Reiffers, J. ; Ringden, O. ; Nikoskelainen, J. ; Van Lint, M. T. ; Vernant, J. P. ; Zwaan, F. E. / Allogeneic bone marrow transplantation in 24 patients with multiple myeloma reported to the EBMT registry. In: Hematological Oncology. 1988 ; Vol. 6, No. 2. pp. 181-186.
@article{7060048ce1b64bbdb721ebc5e06c826f,
title = "Allogeneic bone marrow transplantation in 24 patients with multiple myeloma reported to the EBMT registry",
abstract = "Twenty-four patients with multiple myeloma received an allogeneic bone-marrow graft from HLA-compatible sibling donors (n = 23), or a twin donor (n = 1). Eighteen patients are alive, 1-36 months post bone marrow transplantation (median 14 months). Ten of these patients had no signs of multiple myeloma as judged by immunoglobulins in serum, light chains in urine, or the percentage of plasma-cells in bone-marrow aspirate. Bone lesions on X-ray were mainly unchanged. Six patients died from transplant-related complications 3 weeks to 5 months post transplantation. One of these patients had severe acute graft-versus-host disease (aGVHD). In other patients aGVHD was a minor problem. Allogeneic bone-marrow transplantation appears to be a promising method for treatment of a selected group of patients with multiple myeloma.",
author = "G. Gahrton and S. Tura and M. Flesch and A. Gratwohl and P. Gravett and A. Lindeberg and G. Lucarelli and M. Michallet and J. Reiffers and O. Ringden and J. Nikoskelainen and {Van Lint}, {M. T.} and Vernant, {J. P.} and Zwaan, {F. E.}",
year = "1988",
doi = "10.1002/hon.2900060219",
language = "English",
volume = "6",
pages = "181--186",
journal = "Hematological Oncology",
issn = "0278-0232",
publisher = "wiley",
number = "2",

}

TY - JOUR

T1 - Allogeneic bone marrow transplantation in 24 patients with multiple myeloma reported to the EBMT registry

AU - Gahrton, G.

AU - Tura, S.

AU - Flesch, M.

AU - Gratwohl, A.

AU - Gravett, P.

AU - Lindeberg, A.

AU - Lucarelli, G.

AU - Michallet, M.

AU - Reiffers, J.

AU - Ringden, O.

AU - Nikoskelainen, J.

AU - Van Lint, M. T.

AU - Vernant, J. P.

AU - Zwaan, F. E.

PY - 1988

Y1 - 1988

N2 - Twenty-four patients with multiple myeloma received an allogeneic bone-marrow graft from HLA-compatible sibling donors (n = 23), or a twin donor (n = 1). Eighteen patients are alive, 1-36 months post bone marrow transplantation (median 14 months). Ten of these patients had no signs of multiple myeloma as judged by immunoglobulins in serum, light chains in urine, or the percentage of plasma-cells in bone-marrow aspirate. Bone lesions on X-ray were mainly unchanged. Six patients died from transplant-related complications 3 weeks to 5 months post transplantation. One of these patients had severe acute graft-versus-host disease (aGVHD). In other patients aGVHD was a minor problem. Allogeneic bone-marrow transplantation appears to be a promising method for treatment of a selected group of patients with multiple myeloma.

AB - Twenty-four patients with multiple myeloma received an allogeneic bone-marrow graft from HLA-compatible sibling donors (n = 23), or a twin donor (n = 1). Eighteen patients are alive, 1-36 months post bone marrow transplantation (median 14 months). Ten of these patients had no signs of multiple myeloma as judged by immunoglobulins in serum, light chains in urine, or the percentage of plasma-cells in bone-marrow aspirate. Bone lesions on X-ray were mainly unchanged. Six patients died from transplant-related complications 3 weeks to 5 months post transplantation. One of these patients had severe acute graft-versus-host disease (aGVHD). In other patients aGVHD was a minor problem. Allogeneic bone-marrow transplantation appears to be a promising method for treatment of a selected group of patients with multiple myeloma.

UR - http://www.scopus.com/inward/record.url?scp=0023813664&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023813664&partnerID=8YFLogxK

U2 - 10.1002/hon.2900060219

DO - 10.1002/hon.2900060219

M3 - Article

VL - 6

SP - 181

EP - 186

JO - Hematological Oncology

JF - Hematological Oncology

SN - 0278-0232

IS - 2

ER -